Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
Early-stage NSCLC
Economic burden
Locorregional relapse
Metastatic relapse
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
21 Feb 2023
21 Feb 2023
Historique:
received:
11
10
2022
accepted:
07
02
2023
entrez:
22
2
2023
pubmed:
23
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
There are scarce data of the costs of non-small cell lung cancer (NSCLC) recurrence in Spain. The objective of this study is to assess the economic burden of disease recurrence, for both locoregional and/or metastatic relapses, after appropriate early-stage NSCLC treatment in Spain. A two-round consensus panel of Spanish oncologists and hospital pharmacists was conducted to collect information on patient's flow, treatments, use of healthcare resources and sick leaves in patients with relapsed NSCLC. A decision-tree model was developed to calculate the economic burden of disease recurrence after appropriate early-stage NSCLC. Both direct and indirect costs were considered. Direct costs included drug acquisition and healthcare resources costs. Indirect costs were estimated using the human-capital approach. Unit costs were obtained from national databases (euros of 2022). A multi-way sensitivity analysis was performed to provide a range to the mean values. Among a cohort of 100 patients with relapsed NSCLC, 45 patients would have locoregional relapse (36.3 would eventually progress to metastasis and 8.7 would be considered in remission) and 55 patients would have metastatic relapse. Over time, 91.3 patients would experience a metastatic relapse (55 as first relapse and 36.6 after previous locoregional relapse). The overall cost incurred by the 100-patients cohort is €10,095,846 (€9,336,782 direct costs, €795,064 indirect costs). The average cost of a locoregional relapse is €25,194 (€19,658 direct costs, €5536 indirect costs), while the average cost a patient with metastasis who receives up to 4 lines of treatment is €127,167 (€117,328 direct, €9839 indirect). To our knowledge, this is the first study that specifically quantifies the cost of relapse in NSCLC in Spain. Our findings shown that the overall cost of a relapse after appropriate treatment of early-stage NSCLC patients is substantial, and it increases considerably in the metastatic relapse setting, mainly due to the high cost and long duration of first-line treatments.
Sections du résumé
BACKGROUND
BACKGROUND
There are scarce data of the costs of non-small cell lung cancer (NSCLC) recurrence in Spain. The objective of this study is to assess the economic burden of disease recurrence, for both locoregional and/or metastatic relapses, after appropriate early-stage NSCLC treatment in Spain.
MATERIALS AND METHODS
METHODS
A two-round consensus panel of Spanish oncologists and hospital pharmacists was conducted to collect information on patient's flow, treatments, use of healthcare resources and sick leaves in patients with relapsed NSCLC. A decision-tree model was developed to calculate the economic burden of disease recurrence after appropriate early-stage NSCLC. Both direct and indirect costs were considered. Direct costs included drug acquisition and healthcare resources costs. Indirect costs were estimated using the human-capital approach. Unit costs were obtained from national databases (euros of 2022). A multi-way sensitivity analysis was performed to provide a range to the mean values.
RESULTS
RESULTS
Among a cohort of 100 patients with relapsed NSCLC, 45 patients would have locoregional relapse (36.3 would eventually progress to metastasis and 8.7 would be considered in remission) and 55 patients would have metastatic relapse. Over time, 91.3 patients would experience a metastatic relapse (55 as first relapse and 36.6 after previous locoregional relapse). The overall cost incurred by the 100-patients cohort is €10,095,846 (€9,336,782 direct costs, €795,064 indirect costs). The average cost of a locoregional relapse is €25,194 (€19,658 direct costs, €5536 indirect costs), while the average cost a patient with metastasis who receives up to 4 lines of treatment is €127,167 (€117,328 direct, €9839 indirect).
CONCLUSIONS
CONCLUSIONS
To our knowledge, this is the first study that specifically quantifies the cost of relapse in NSCLC in Spain. Our findings shown that the overall cost of a relapse after appropriate treatment of early-stage NSCLC patients is substantial, and it increases considerably in the metastatic relapse setting, mainly due to the high cost and long duration of first-line treatments.
Identifiants
pubmed: 36809990
doi: 10.1186/s12890-023-02356-0
pii: 10.1186/s12890-023-02356-0
pmc: PMC9942326
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Transl Lung Cancer Res. 2019 Aug;8(4):461-475
pubmed: 31555519
Cancers (Basel). 2021 Aug 10;13(16):
pubmed: 34439189
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Clin Transl Oncol. 2019 Jan;21(1):3-17
pubmed: 30446985
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Ann Thorac Surg. 2012 Jun;93(6):1813-20; discussion 1820-1
pubmed: 22542070
Sci Rep. 2019 Apr 9;9(1):5821
pubmed: 30967657
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Clin Oncol. 2020 Nov 1;38(31):3592-3603
pubmed: 32780660
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Cancer Med. 2020 May;9(10):3310-3318
pubmed: 32167664
BMC Health Serv Res. 2015 Feb 21;15:70
pubmed: 25889153
Cancer. 2019 Mar 15;125(6):892-901
pubmed: 30512189
Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109
pubmed: 29183778
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Gac Sanit. 2022 May-Jun;36(3):246-252
pubmed: 33612313
PLoS One. 2018 Aug 27;13(8):e0202865
pubmed: 30148862
J Oncol Pharm Pract. 2019 Jul;25(5):1099-1104
pubmed: 29792122
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
Ann Oncol. 2018 Jun 1;29(6):1409-1416
pubmed: 29668860
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70
pubmed: 29168933
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2005 Nov 20;23(33):8380-8
pubmed: 16293868
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Clin Lung Cancer. 2017 Jan;18(1):60-67
pubmed: 27919627
Clin Transl Oncol. 2011 Jul;13(7):460-71
pubmed: 21775273
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Thorac Oncol. 2018 Dec;13(12):1906-1918
pubmed: 30217492
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
BMC Res Notes. 2010 Jul 14;3:195
pubmed: 20630074
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Thorac Cancer. 2021 Jan;12(1):13-20
pubmed: 33219738
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
Clin Transl Oncol. 2020 Jul;22(7):989-1003
pubmed: 31598903
J Thorac Oncol. 2021 Nov;16(11):1909-1924
pubmed: 34311108
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Lung Cancer. 2018 Oct;124:298-309
pubmed: 29961557
BMC Health Serv Res. 2020 Nov 26;20(1):1089
pubmed: 33243262
Clinicoecon Outcomes Res. 2020 Jan 15;12:23-33
pubmed: 32021337
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
Curr Oncol. 2016 Feb;23(Suppl 1):S7-S13
pubmed: 26985151
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28748556
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Clin Lung Cancer. 2014 Jul;15(4):258-65
pubmed: 24954228
Transl Lung Cancer Res. 2014 Aug;3(4):242-9
pubmed: 25806307
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Am Soc Clin Oncol Educ Book. 2019 Jan;39:553-562
pubmed: 31099691
Health Syst Transit. 2018 May;20(2):1-179
pubmed: 30277216
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Sci Rep. 2017 Oct 19;7(1):13543
pubmed: 29051570
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977